8-K: Indivior PLC Proposes UK to US Re-domestication

Indivior PLC plans to re-domicile from the U.K. to Delaware, establishing Indivior Pharmaceuticals, Inc. as its new U.S. holding company to maximize U.S. listing benefits.

Summary

• Indivior PLC, a U.K. company, proposes to change its domicile to the U.S. by establishing a new Delaware corporation, Indivior Pharmaceuticals, Inc., as its new holding company.
• The re-domestication will be implemented through a U.K. Court-sanctioned Scheme of Arrangement.
• Shareholders will receive one Indivior Pharmaceuticals Share for every one Indivior Share held at the Scheme Record Time.
• Indivior PLC will become a direct wholly-owned subsidiary of Indivior Pharmaceuticals, Inc. following the Scheme.
• The Scheme requires approval from Indivior Shareholders at a Court Meeting and an Extraordinary General Meeting, as well as sanction from the U.K. Court.
• The Indivior Board unanimously recommends that shareholders vote in favor of the Scheme and related Special Resolutions.
• The Scheme is currently anticipated to become effective on January 23, 2026, with trading of Indivior Pharmaceuticals Shares on Nasdaq commencing on January 26, 2026.

Sentiment

Score: 7

Explanation: The re-domestication is presented as a strategic move to optimize the company's U.S. listing benefits, simplify governance, and align with its shareholder base. While there are some noted negatives like the loss of U.K. Takeover Code protections and a short-term tax rate increment, the overall tone and stated benefits suggest a positive strategic direction for the company.

Positives

• Maximizes the benefits of the Group's U.S. stock listing on Nasdaq.
• Expands U.S. capital markets presence and increases potential U.S. equity indexation.
• Simplifies corporate governance and reduces complexity.
• Further positions Indivior as a U.S.-based treatment innovator, enabling closer collaboration with public health leaders on advancing SUBLOCADE for opioid use disorder.
• Aligns the Group's domicile with the significant majority of the existing shareholder base.
• The rights attaching to the new Indivior Pharmaceuticals Shares will be substantially the same as those attaching to the current Indivior Shares.
• The Scheme is intended to qualify as a tax-free reorganization or exchange for U.S. federal income tax purposes, and generally no U.K. tax liabilities are expected for U.K. Holders arising from the implementation.

Negatives

• The U.K. City Code on Takeovers and Mergers (the Code) will no longer apply to takeover offers for Indivior Pharmaceuticals after the Scheme Effective Time, removing specific protections for shareholders (e.g., mandatory cash offer requirements).
• The Group expects a modest increment in the effective tax rate in the short to mid-term, although this is expected to substantially reverse over time.
• Dividends paid on Indivior Pharmaceuticals Shares to Non-U.S. Holders will generally be subject to a 30% U.S. federal withholding tax, unless eligible for a reduced rate under an applicable income tax treaty.
• Indivior Pharmaceuticals Depositary Interests (DIs) may be treated as assets situated in the U.K. for U.K. inheritance tax purposes, potentially leading to liability even for non-long-term U.K. residents.
• Mandates relating to the payment of dividends by electronic bank transfer for Indivior DI Holders and Indivior CSN Holders will be revoked and require resubmission.

Risks

• If the U.S. Internal Revenue Service successfully challenges the intended tax-free treatment of the Scheme, holders could be subject to U.S. federal income tax upon the receipt of Indivior Pharmaceuticals Shares.
• The Scheme will lapse if it has not become effective by December 31, 2026 (or a later agreed date), in which case the re-domestication will not proceed.
• The Indivior Pharmaceuticals Board has discretion over whether to declare or pay dividends, subject to constitutional documents and Delaware law.
• The issuance of Indivior Pharmaceuticals Preferred Shares could decrease the trading price of common shares, restrict dividends, dilute voting power, impair liquidation rights, or delay or prevent a change in control.
• The exclusive forum provision in the Indivior Pharmaceuticals Certificate of Incorporation designates Delaware courts as the sole and exclusive forum for certain actions, and federal district courts for U.S. Securities Act claims, potentially limiting shareholder choice of venue.
• The DI Depositary and any custodian or agent are entitled to be indemnified against liabilities incurred in their obligations and may make deductions from income or capital receipts or sell shares to cover costs or tax liabilities.
• The DI Depositary's liability is excluded or limited for acts or omissions of Indivior Pharmaceuticals, the CREST Operator, or any third party reasonably appointed to provide services.
• The DI Depositary may terminate or amend the Indivior Pharmaceuticals DI Deed.
• The CSN Nominee is not responsible for losses incurred from acts or omissions of the CREST member through whom messages are delivered into CREST on its behalf or arising from CREST.
• The CSN Nominee may terminate a CSN Holder's participation in the Indivior Pharmaceuticals CSN under certain conditions.

Future Outlook

The Group expects to more closely align its corporate governance arrangements with those followed by U.S. domestic issuers, complying with U.S. corporate governance standards and reporting rules (SEC, Nasdaq, Delaware law). The compensation structure for senior management and Non-Executive Directors will continue to be brought into line with U.S. market practice. The Scheme is expected to result in a modest increment in the Group's effective tax rate in the short to mid-term, which is anticipated to substantially reverse over time.

Management Comments

• "The Indivior Board is unanimously recommending that you vote in favour of the Scheme."
• "The Indivior Board is recommending the proposed change in domicile of the parent company of the Group to maximize the benefits of the Groups U.S. stock listing."
• "Inserting a new U.S. parent company... will also align the Groups domicile with the significant majority of the existing shareholder base."

Industry Context

This re-domestication aligns with a broader trend for companies with significant U.S. operations and shareholder bases to consolidate their listing and corporate domicile in the U.S. The move follows the cancellation of Indivior's secondary listing in London, indicating a strategic focus on enhancing U.S. capital market access, simplifying governance, and better positioning the company within the U.S. regulatory and public health landscape, particularly for its opioid use disorder treatment, SUBLOCADE.

Comparison to Industry Standards

• Indivior Pharmaceuticals will comply with U.S. corporate governance standards, including rules on director independence, audit, nomination, and compensation committees, and shareholder approval requirements, aligning with U.S. domestic issuers.
• The company will be subject to the U.S. Exchange Act (requiring Form 10-K, 10-Q, 8-K filings) and the U.S. Sarbanes-Oxley Act (requiring management reports on internal controls and auditor attestation), which are standard for U.S. public companies.
• The governing company law will transition from English company law to Delaware General Corporation Law, which introduces differences in shareholder rights, board duties, and corporate procedures (e.g., dividends, share buybacks, pre-emption rights, director removal, indemnification).
• Unlike English law, Delaware law generally does not require shareholder approval for share buybacks if capital is not impaired, and shareholders typically do not have pre-emptive rights unless specified in the certificate of incorporation.
• Delaware law allows for director removal with or without cause by a majority shareholder vote for unclassified boards, differing from the absolute power under English law.
• Delaware law permits broader indemnification of directors and officers compared to English law, which generally prohibits protection from liabilities arising from negligence or breaches of duty.
• The compensation structure for senior management and Non-Executive Directors will be brought into line with U.S. market practice for U.S. listed companies of a similar size and profile.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will exchange U.K. shares for U.S. shares on a 1:1 basis, subject to U.S. corporate governance and tax laws. They will lose U.K. Takeover Code protections but may benefit from increased U.S. equity indexation and capital markets presence.
• Employees: Existing equity awards under Legacy Share Plans will be assumed by Indivior Pharmaceuticals and exchanged for awards relating to the new U.S. shares on a 1:1 basis, with other terms remaining similar. A new U.S.-style omnibus equity incentive plan (New Share Plan) will be adopted for future awards.
• Management: The board and management will largely remain the same. Compensation structure will align with U.S. market practice.
• Public Health Leaders: Closer collaboration is expected on advancing SUBLOCADE for opioid use disorder due to the company's U.S. positioning.

Next Steps

• Shareholders to vote on the Scheme at the Court Meeting and Special Resolutions at the Extraordinary General Meeting on December 11, 2025.
• Court Hearing to sanction the Scheme on January 22, 2026.
• Scheme to become effective on January 23, 2026 (expected).
• Indivior Pharmaceuticals Shares to commence trading on Nasdaq on January 26, 2026 (expected).
• Indivior PLC to be re-registered as a private company limited by shares.
• Adoption of Post-Scheme Articles of Association for Indivior PLC.
• Indivior Pharmaceuticals Board to pass resolutions for its operation, including auditor appointment, transfer agent, compensation policy, committee formation, and adoption of the New Share Plan.
• Indivior Pharmaceuticals to assume Legacy Share Plans and file corresponding SEC registration statements.
• Employee benefit trust to be wound up prior to the Scheme Effective Date.
• Shareholders to exchange old Indivior Share certificates for new Indivior Pharmaceuticals Shares (via DRS).
• Indivior DI Holders to have Indivior DIs replaced by Indivior Pharmaceuticals DIs.
• Indivior CSN Holders to have Indivior DIs in CSN replaced by Indivior Pharmaceuticals DIs in new CSN.
• Shareholders who are Indivior DI Holders or CSN Holders will need to re-submit dividend payment mandates.

Key Dates

Recommendation

The proposed re-domestication is a strategic move aimed at optimizing Indivior's U.S. market presence and simplifying its corporate structure, which are generally positive long-term developments. The 1:1 share exchange and intended tax-free treatment for shareholders are favorable. However, the loss of U.K. Takeover Code protections and the anticipated short-to-mid-term increase in the effective tax rate introduce new considerations. While the strategic rationale is sound, the immediate financial impact is not explicitly positive, and the changes in governance and shareholder rights warrant a 'hold' recommendation as investors assess the full implications of the new domicile and regulatory environment.

Keywords

Indivior PLC, re-domestication, Delaware, Nasdaq, corporate governance, SEC filing, Scheme of Arrangement, pharmaceuticals, SUBLOCADE, opioid use disorder, U.S. listing, equity indexation, taxation, shareholder rights